The group’s lead next-gen exon skipper beats a low bar set by Exondys, but adverse events loom large.
A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
Amryt marches ahead, but gene therapies from Krystal, Abeona and Castle Creek are heading towards data readouts.
A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
A pivotal win puts nirsevimab on track to be filed next year, but the reimbursement hurdle looms.
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.